Tickers
Tiziana Life Sciences (Nasdaq: TLSA) said it will host an investor call and webcast with key opinion leaders to discuss positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis. The company did not disclose specific efficacy or safety data in the announcement. The call is scheduled to follow the release of the trial’s topline results.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) said it will host a conference call and webcast with Key Opinion Leaders (KOLs) to discuss positive topline results from its Phase 2a INFORM-MS trial, according to a company announcement dated Nov. 05, 2026.
Trial and Candidate
The INFORM-MS trial is a Phase 2a study of intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). Tiziana describes foralumab as a fully human anti-CD3 monoclonal antibody and its lead development candidate. The company characterizes itself as a biotechnology company developing immunomodulation therapies.
What the Announcement Covers
- The announcement states that the topline results are positive.
- It does not disclose specific efficacy or safety data from the trial.
- The call and webcast are intended to discuss the topline results with KOLs.
Call Details
The announcement did not include the date, time or access details for the conference call and webcast, nor did it identify the participating Key Opinion Leaders.
Company Information
Tiziana is headquartered in Boston and trades on Nasdaq under the symbol TLSA.